It is Time to “Outperform” InflaRx (IFRX), BMO Capital Says. Stock May Be Worth $45.0

July 13, 2018 - By Jenna Rose

Why Has BMO Capital Given InflaRx (IFRX) a $45.0 Price Target

BMO Capital analyst initiated coverage on InflaRx (IFRX) with a $45.0 price target and “Outperform” rating. The price target suggests a potential upside of 32.98 % from firm’s stock close price.

InflaRx N.V. (NASDAQ:IFRX) Ratings Coverage

Among 5 analysts covering InflaRx (IFRX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. InflaRx has $55 highest and $3600 lowest target. $44.80’s average target is 32.39% above currents $33.84 stock price. InflaRx had 9 analyst reports since February 8, 2018 according to SRatingsIntel. The stock has “Buy” rating by FBR Capital on Thursday, March 8. As per Thursday, May 17, the company rating was maintained by FBR Capital. The rating was maintained by FBR Capital on Thursday, March 29 with “Buy”. Leerink Swann maintained InflaRx N.V. (NASDAQ:IFRX) rating on Friday, May 18. Leerink Swann has “Buy” rating and $4200 target. The stock of InflaRx N.V. (NASDAQ:IFRX) earned “Buy” rating by Leerink Swann on Monday, April 2. The rating was initiated by FBR Capital with “Buy” on Wednesday, February 7.

The stock increased 11.65% or $3.53 during the last trading session, reaching $33.84. About 24,412 shares traded. InflaRx N.V. (IFRX) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Analysts await InflaRx N.V. (NASDAQ:IFRX) to report earnings on August, 16. After $-0.49 actual earnings per share reported by InflaRx N.V. for the previous quarter, Wall Street now forecasts -18.37 % EPS growth.

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. The company has market cap of $868.41 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: which released: “BMO Capital Starts Inflarx NV (IFRX) at Outperform” on July 13, 2018, also with their article: “Biotech: Take It On The Run” published on July 05, 2018, published: “InflaRx: Buy The Dip” on June 29, 2018. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: and their article: “Benzinga’s Top Upgrades, Downgrades For July 13, 2018” published on July 13, 2018 as well as‘s news article titled: “Premarket analyst action – healthcare” with publication date: July 13, 2018.

InflaRx N.V. (NASDAQ:IFRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.